1. Evo312: An Evodiamine Analog and Novel PKCβI Inhibitor with Potent Antitumor Activity in Gemcitabine-Resistant Pancreatic Cancer.
- Author
-
Bae ES, Hong J, Lim Y, Byun WS, Chun S, Hong S, and Lee SK
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors chemical synthesis, Protein Kinase Inhibitors chemistry, Mice, Nude, Protein Kinase C beta antagonists & inhibitors, Protein Kinase C beta metabolism, Xenograft Model Antitumor Assays, Structure-Activity Relationship, Mice, Inbred BALB C, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Gemcitabine, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Deoxycytidine chemistry, Drug Resistance, Neoplasm drug effects, Quinazolines pharmacology, Quinazolines chemistry, Quinazolines chemical synthesis, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Apoptosis drug effects, Cell Proliferation drug effects
- Abstract
As an obstinate cancer pancreatic cancer (PC) poses a major challenge due to limited treatment options which include resection surgery, radiation therapy, and gemcitabine-based chemotherapy. In cancer cells, protein kinase C βI (PKCβI) participates in diverse cellular processes, including cell proliferation, invasion, and apoptotic pathways. In the present study, we created a scaffold to develop PKCβI inhibitors using evodiamine-based synthetic molecules. Among the candidate inhibitors, Evo312 exhibited the highest antiproliferative efficacy against PC cells, PANC-1, and acquired gemcitabine-resistant PC cells, PANC-GR. Additionally, Evo312 robustly inhibited PKCβI activity. Mechanistically, Evo312 effectively suppressed the upregulation of PKCβI protein expression, leading to the induction of cell cycle arrest and apoptosis in PANC-GR cells. Furthermore, Evo312 exerted an antitumor activity in a PANC-GR cell-implanted xenograft mouse model. These findings position Evo312 as a promising lead compound for overcoming gemcitabine resistance in PC through novel mechanisms.
- Published
- 2024
- Full Text
- View/download PDF